Obstructive sleep apnea and idiopathic intracranial hypertension: a systematic review and meta-analysis.

Can J OphthalmolMay 27, 2026 (epub)
Clinical ResearchNeurologyPulmonology

Abu Bakar Butt, Afreen Ahmad, Bhadra Pandya et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed the prevalence of obstructive sleep apnea (OSA) in adults with idiopathic intracranial hypertension (IIH) using polysomnography and the Berlin Questionnaire. Among 11 studies, the pooled prevalence of OSA in IIH patients was found to be 0.44 (95% CI: 0.26-0.63) based on PSG data, indicating a significant association that warrants further investigation.

Key findings

  • The pooled prevalence of OSA in IIH patients was 0.44 (95% CI: 0.26-0.63) based on PSG.
  • Excluding high-risk studies, the pooled prevalence increased to 0.53 (95% CI: 0.32-0.74).
  • The pooled prevalence of OSA based on the Berlin Questionnaire was 0.65 (95% CI: 0.54-0.74).
  • Funnel plot asymmetry indicated potential publication bias, and the certainty of evidence was very low.

Why it matters

Understanding the prevalence of OSA in patients with IIH is crucial for improving diagnosis and management strategies, as both conditions share overlapping risk factors and can significantly impact patient outcomes.

What to keep in mind

The certainty of evidence was very low, and there was potential publication bias indicated by funnel plot asymmetry.

Source

PubMed · PMID 42150616

Published in Can J Ophthalmol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.